Axsome Therapeutics, Inc

Headquarters

New York, NY

UEI

KGMGGVWRZRW4

CAGE

7J7H1

Founded in January 2012 by physician Herriot Tabuteau, Axsome Therapeutics is a New York biopharmaceutical company focused on central nervous system conditions with limited treatment options. Its work centers on developing therapies intended to give patients and physicians new approaches where existing care falls short.

• Supernus Pharmaceuticals, IncFounded by Jack A. Khattar in 2005, Supernus Pharmaceuticals is a Rockville biopharmaceutical company that develops and commercializes medicines for central nervous system diseases. With more than 30 years of product-development expertise, it uses proprietary technologies and an active clinical pipeline to advance treatments in neurology and psychiatry, while marketing its medicines in the United States through specialty sales forces.ROCKVILLE, MD
• Cognition Therapeutics, IncCognition Therapeutics is a clinical-stage neuroscience company developing oral medicines for age-related neurodegenerative diseases, with its research centered on zervimesine (CT1812), an investigational therapy intended to protect synapses from toxic protein oligomers. The company brings 20 years of mechanistic, translational, and clinical research to Alzheimer’s disease and dementia with Lewy bodies, where its once-daily small-molecule approach is being evaluated in Phase 2 studies. Headquartered in Purchase, New York, Cognition also uses clinical research and patient-caregiver engagement to address conditions that have historically received limited investment.PURCHASE, NY
• Gilgamesh PharmaGilgamesh Pharma is a New York clinical-stage neuroscience biotech developing novel chemical entities for psychiatric disease, with an emphasis on rapid-acting and durable therapies rather than symptom management alone. Its in-house discovery platform combines medicinal chemistry, neurocircuitry science, and computational modeling, and has produced clinical programs including blixeprodil and a neuroplastogen partnership with AbbVie. The company’s first clinical asset, bretisilocin, was acquired by AbbVie after advancing to Phase 2.New York, NY
• Perception NeurosciencePerception Neuroscience is a New York City-based clinical-stage biopharmaceutical company developing PCN-101, an R-ketamine compound intended to provide faster-acting treatment options for serious psychiatric disorders. The company holds an exclusive license to intellectual property originating from research at Japan’s Chiba University and has advanced PCN-101 through Phase 1 studies and an FDA-cleared IND into Phase 2 clinical development. Perception is majority-owned by atai Life Sciences and partnered with Otsuka Pharmaceutical on development in Japan.New York, NY